The influence of vancomycn on tobramycin nephrotoxicity was assessed in male Fischer rats. Treatment groups included controls receiving diluent and groups receiving vancomycin alone at a dosage of 200 mg/kg (body weight) per day, tobramycin alone at a dosage of 80 mg/kg per day, and a combination of vancomycin and tobramycin at the above dosages. All regimens were injected on a twice-a-day schedule. The animals were sacrificed on days 1, 3, 10, 14, 17, and 21. When compared with controls, animals receiving vancomycin alone exhibited no detectable renal toxicity. Compared with the case with controls, tobramycin alone was toxic, as manifested by lower mean animal weights, increased blood urea nitrogen concentrations on days 14 and 17 (P < 0.005), increased serum creatinine concentrations on days 17 and 21 (P < 0.005), and the presence of renal cortical tubular necrosis and regeneration. When compared with tobramycin alone, the combination of vancomycin and tobramycin caused earlier and more severe toxicity. By day 10, the magnitude of weight loss, the rise in blood urea nitrogen, and the increase in serum creatinine concentration were all greater in the rats given the combination of vancomycin plus tobramycin than in the animals given tobramycin alone (P < 0.005). In addition, there was more proximal tubular necrosis and regeneration in rats given vancomycin plus tobramycin compared with those given tobramycin alone. In this animal model, vancomycin alone caused no detectable renal injury, tobramycin alone produced minimal proximal tubular damage, and the combination of vancomycin and tobramycin resulted in a greater degree of kidney injury than observed with tobramycin alone.
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In recent years, clinical indications for combination antimicrobic therapy with vancomycin and an aminoglycoside have increased. Selected examples are prosthetic valve endocarditis caused by Staphylococcus epidermidis (9) , serious infections caused by methicillin-resistant Staphylococcus aureus (10) , and endocarditis caused by group D streptococci in patients allergic to penicillin (8, 15) .
The dose-dependent nephrotoxic potential of the aminoglycosides is well known. The nephrotoxic potential of vancomycin is uncertain. Early clinical studies with vancomycin described patients who developed granular casts, increases in blood urea nitrogen (BUN) , and severe anemia and even died from acute renal failure. Subsequently, impurities present in the initial vancomycin preparations were removed (7, 17) . More recent clinical studies describe a very low incidence of renal injury in patients given only vancomycin (1, 3, 4, 13, 14) . However, it has been suggested that vancomycin given concomitantly with an aminoglycoside may increase the frequency of aminoglycoside nephrotoxicity (3). Farber and Moellering described, retrospectively, more nephrotoxicity in patients given the combination of vancomycin and an aminoglycoside than in patients administered only vancomycin (3) . Unfortunately, the latter study did not include a control group of patients given only an aminoglycoside.
The experiments described below were designed to determine whether the concurrent administration of vancomycin and tobramycin alters the nephrotoxicity caused by tobramycin alone in an animal model of aminoglycoside toxicity (5, 6, 11 also determined by fluorescence immunoassay (American Diagnostics, Newport Beach, Calif.).
Sacrifice procedure. Animals were sacrificed under ether anesthesia 18 h after the last antibiotic injection following 1, 3, 10, 14, 17, or 21 days of treatment. Each sacrifice day included three control animals, four rats given tobramycin alone, five rats given vancomycin alone, and five animals given the combination of vancomycin and tobramycin. Serum creatinine and BUN determinations were performed by standard methods with blood collected by cardiac puncture at necropsy. One kidney was sectioned in the median sagittal plane, and half was placed in 10% Formalin for histologic preparation. The remaining renal tissue was weighed, placed in 3 ml of 4°C Tris buffer (pH 7.2), and processed for renal antibiotic concentrations.
Renal antibiotic concentration. Renal tobramycin and vancomycin concentrations were determined by fluorescence immunoassay. In preliminary experiments, Tris buffer and renal tissue from rats not given either experimental drug were assayed for possible nonspecific fluorescence. At the dilutions of homogenate used to quantitate test drugs in treated animals, there was no nonspecific fluorescence. Kidneys from untreated animals were also spiked with known amounts of tobramycin or vancomycin to simulate concentrations expected in test animals. These were assayed to calculate percent recovery. Tobramycin recovery was 59.9 ± 6.9% (n = 6), and vancomycin recovery was 72.4 ± 7.9% (n = 6).
Kidney specimens were homogenized in Tris buffer and then centrifuged at 2,000 x g for 10 min. The (Table 1) . In contrast, after 14 days, the weight of rats given tobramycin alone was 212 ± 17 g, compared with 230 ± 12 g for control rats (P < 0.01). The lower mean weight compared with the control weight persisted through day 17 for the group given tobramycin only (P < 0.005). Of particular interest, animals given tobramycin only gained weight during the last 7 days of drug exposure ( Fig. 1; Table 1 ). Rats given the combination of tobramycin plus vancomycin experienced more weight loss than animals given tobramycin alone. After 10 days, the rats given tobramycin only weighed 218 ± 14 g, compared with 204 ± 11 g for the combinationtreatment animals (P < 0.05). After 14 days, the weight difference was again significant (P < 0.005). Even combination-treatment rats gained weight during the last 7 days of drug exposure.
Renal function. BUN results in rats given vancomycin alone were no different from results for controls at all time points sampled ( and tobramycin (Fig. 1) . After 10 days, the BUN in the rats given vancomycin plus tobramycin was significantly greater than the value in rats given tobramycin alone (P < 0.005). The difference in the two groups disappeared on days 14 and 17 but was again evident after 21 days (P < 0.01).
Animals given vancomycin alone had serum creatinine values no different from those of control animals. Rats given tobramycin alone had elevated serum creatinine values at 17 and 21 days as compared with controls (P < 0.005). Significant creatinine elevations occurred earlier in rats given vancomycin plus tobramycin. Compared with animals given tobramycin only, the rats given both drugs had elevated serum creatinine by day 3 (P < 0.01); this persisted at day 10 (P < 0.005), but then the difference disappeared on days 14, 17, and 21.
Renal histology. Light microscopy of renal tissue from controls and rats receiving vancomycin only was interpreted as normal in all animals by both pathologists (Fig. 2) . Histologic evidence of tubular necrosis occurred earlier and the approximate percentage of necrotic cells was greater in animals given vancomycin plus tobramycin than in rats given tobramycin alone. The values at day 3 did not achieve statistical significance because of a large deviation surrounding the vancomycin-plus-tobramycin point. At day 10, statistical significance was achieved, with P < 0.01. Histologic evidence of regeneration followed a similar pattern, but the percentage of tubules showing regenerative activity was much greater. Rats given tobramycin alone displayed the greatest degree of tubular regeneration after 17 days (53%), whereas the animals given vancomycin and tobramycin showed the greatest degree of tubular regeneration (75%) after 10 days. Statistical difference was reached between groups at days 10, 14, 17, and 21, with P < 0.01.
Renal antibiotic concentrations. Tobramycin accumulated early in therapy in renal tissue from animals receiving either tobramycin alone or tobramycin and vancomycin (Table 2 ; Fig. 1 ). Renal tobramycin then declined sharply at day 10 in the group receiving combination therapy before reaccumulation after that point. Animals receiving tobramycin alone demonstrated a later decline, at day 14, again before reaccumulation. This resulted in animals receiving tobramycin alone having significantly higher renal tobramycin concentrations than animals receiving the combination of vancomycin and tobramycin at sample days 10, 14, and 17 (P < 0.01).
Vancomycin accumulated in renal tissue in animals receiving vancomycin alone or the combination of tobramycin plus vancomycin through day 14 of treatment ( Table 2 ). The renal vancomycin level then plateaued for the group receiving vancomycin alone, while it continued to rise in the group receiving combination treatment. This resulted in the animals receiving both tobramycin and vancomycin having significantly higher renal vancomycin levels at days 17 and 21 (P < 0.05).
DISCUSSION
In these experiments, vancomycin at a dosage of 200 mg/kg per day caused no detectable nephrotoxicity when given alone to male Fischer rats. The absence of renal injury in these experiments does not preclude kidney toxicity in future experiments which might increase the vancomycin dosage, alter the dosage frequency or route, use a different sex or strain of rat, or change other variables. The daily dosage of vancomycin used in our studies was modest as judged by the mean 1-h-postdose serum concentration of 26 jig/ml, which is in the human therapeutic range. Lastly, a (12) . Other parameters of more severe injury, such as serum creatinine and renal histology, remained normal (12) . In contrast, Aronoffet al. detected no alteration in male Sprague-Dawley rats given a maximum dosage of 400 mg/kg per day for 28 days (2) . After 28 days, only minor histologic changes were observed in both treated and control rats (2) .
In our experiments, tobramycin at a dose of 80 mg/kg per day, divided into two daily injections, was toxic based on 22 WOOD ET AL.
..ftc multiple parameters: early animal weight loss and delayed weight gain, elevated BUN and serum creatinine measurements, and histologic evidence of cortical tubular necrosis and tubular regeneration. Concomitant vancomycin both amplified and accelerated the manifestations of tobramycin nephrotoxicity. Rats given both drugs displayed, at an earlier time, more weight loss, higher serum creatinine and BUN concentrations, and more histologic damage compared with animals given tobramycin alone. These results confirm and extend the observations of Wold and Turnipseed (16) . These workers gave rats tobramycin at 60 mg/kg per day combined with vancomycin in increasing dosage from 75 to 150 mg/kg per day. Renal function was determined only after 4 days of drug exposure. Impairment of renal function was observed only with the combination of tobramycin and the larger vancomycin dosage (16). Marre et al. also showed synergistic toxicity with the combination of vancomycin and tobramycin (12) .
These animal studies may have clinical import. Farber and Moellering retrospectively studied vancomycin nephrotoxicity from 1974 to 1981 (3). A total of 100 patient courses of vancomycin therapy were evaluated. By their criteria, the incidence of nephrotoxicity in patients given vancomycin alone was 5%, and in patients given an aminoglycoside concurrently, the incidence of nephrotoxicity was 35%. This high incidence of toxicity suggested the possibility of an enhancement of aminoglycoside nephrotoxicity by vancomycin. However, the study of Farber and Moellering was retrospective and did not include a patient group that received only an aminoglycoside (3). In contrast, Mellor et al. recently reported on a prospective series of 34 patients who received 39 courses of vancomycin; 27 patients received concomitant vancomycin-aminoglycoside therapy (13) . Only three patients met the researchers' criteria for nephrotoxicity. The low incidence of renal injury may have precluded recognition of any synergistic toxicity between vancomycin and aminoglycosides (13) . Sorrell and Collignon prospectively investigated vancomycin toxicity in 54 patients, 28 of whom received concomitant aminoglycoside therapy (14) . Nephrotoxicity was detected in 4 of the 28 patients given vancomycin plus an aminoglycoside and in 0 of 26 patients given either vancomycin alone or vancomycin plus drugs other than an aminoglycoside. The latter two studies were prospective (13, 14) , but none of the studies mentioned was randomized, nor did they report the incidence of nephrotoxicity in patients administered an aminoglycoside without vancomycin. Thus, additional prospective, randomized, controlled clinical trials are necessary to determine whether the animal data are valid in patients.
Available experimental data indicate that the aminoglycoside antibiotics accumulate in and ultimately cause necrosis of the cells of the proximal convoluted tubule (5, 11) . Renal handling of aminoglycosides is still incompletely understood. It appears the drugs undergo glomerular filtration with subsequent reabsorption by cells of the proximal tubule. If some tubular secretion occurs, it does not seem a major excretory pathway. It is tubular cell accumulation of aminoglycoside, with subsequent cell necrosis, that is tentatively offered as an explanation for the cyclical changes in the renal aminoglycoside concentration which have been repeatedly observed in animal experiments (5, 6, 11 subsequent rise in renal aminoglycoside concentration temporally correlates with tubular regeneration and perhaps tubular cell reaccumulation of drug (5). In contrast, there is virtually no knowledge of the renal handling or site of kidney accumulation of vancomycin. In our experiments, continued dosing with vancomycin led to a progressive increase in the renal concentration of vancomycin. The renal vancomycin concentration, in contrast to the tobramycin concentration, did not decrease with the wave of proximal tubular necrosis. Indirectly, this observation suggests vancomycin accumulation at a renal site either distinct from or in addition to the proximal tubular cells. Additional studies are needed to determine the site, or sites, of vancomycin accumulation and the overall renal handling of vancomycin.
The mechanism by which vancomycin enhances tobramycin nephrotoxicity is not readily apparent. Enhanced renal accumulation of tobramycin is not a viable explanation, because animals receiving the combination of vancomycin and tobramycin had lower renal tobramycin concentrations than did animals receiving tobramycin alone, at all datum points beyond 3 days. Other hypotheses may surface when the site of renal vancomycin accumulation and the physiologic mechanism of renal vancomycin excretion are known.
In summary, in the animal model used, a modest dosage of vancomycin, which resulted in no toxicity when administered alone, enhanced tobramycin nephrotoxicity.
